{"protocolSection": {"identificationModule": {"nctId": "NCT00060840", "orgStudyIdInfo": {"id": "INOT 41"}, "organization": {"fullName": "Mallinckrodt", "class": "INDUSTRY"}, "briefTitle": "The Effects of Nitric Oxide for Inhalation During Left Ventricular Assists Device (LVAD) Implantation", "officialTitle": "The Effects of Nitric Oxide for Inhalation During Left Ventricular Assist Device (LVAD) Implantation"}, "statusModule": {"statusVerifiedDate": "2016-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2003-07"}, "primaryCompletionDateStruct": {"date": "2008-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2003-05-14", "studyFirstSubmitQcDate": "2003-05-14", "studyFirstPostDateStruct": {"date": "2003-05-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-08-25", "resultsFirstSubmitQcDate": "2010-08-25", "resultsFirstPostDateStruct": {"date": "2010-09-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-07-22", "lastUpdatePostDateStruct": {"date": "2016-08-22", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Mallinckrodt", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the utility of nitric oxide for inhalation during left ventricular assist device (LVAD) implantation following cardiopulmonary bypass (CPB). This is to be assessed by the number of patients in each treatment group meeting failure criteria within 24 hours on study drug, as defined by two or more of the following:\n\n* Left ventricular flow rate index (LVFRI) \u2264 2.0 L/min/m\\^2\n* Administration of \u2265 20 inotropic equivalents (IE)\n\n  * 10 \u00b5g/kg/min dopamine, dobutamine, enoximone or amrinone is equivalent to 10 IE\n  * 0.1 \u00b5g/kg/min epinephrine or norepinephrine is equivalent to 10 IE\n  * 1 \u00b5g/kg/min milrinone is equivalent to 15 IE\n  * 0.1 U/min vasopressin is equivalent to 10 IE\n* Mean arterial pressure (MAP) \u2264 55 mmHg\n* Central venous pressure (CVP) \u2265 16 mmHg\n* Percent mixed venous oxygen saturation (SvO2) \u2264 55%\n\nOr at least one of the following criteria:\n\n* Failure to wean from cardiopulmonary bypass at least once due to hemodynamic failure. Re-initiation of cardiopulmonary bypass to correct bleeding or other technical issues will not be considere 'failure to wean'\n* Death", "detailedDescription": "40 ppm of either nitric oxide for inhalation or N2 (placebo) will be continuously administered to the patient starting at least 5 minutes prior to initiating the first weaning attempt from CPB and continue until the patient is either extubated, has reached failure criteria, or has been treated with study drug for 48 hours following discontinuation of CPB, whichever come first.\n\nAll patients will be monitored peri-operatively with a pulmonary arterial line, central venous line, and systemic arterial line. Baseline data collection by a designated clinical staff member will begin following induction of anesthesia and prior to skin incision. Following a successful wean from cardiopulmonary bypass, post-op data will be collected within 1 hour following end time of surgery. Data will then be collected at 6, 12, 18, 24, and 48 hours from post-op or until extubation, in which case weaning from study drug will begin.\n\nOpen label investigational nitric oxide for inhalation may be administered once a patient meets a minimum of two of the failure criteria or fails to wean at least once due to hemodynamic failure from cardiopulmonary bypass."}, "conditionsModule": {"conditions": ["Congestive Heart Failure"], "keywords": ["Left Ventricular Assist Device Implantation", "Progressive Left Ventricular Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 150, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Inhaled Nitric Oxide", "type": "ACTIVE_COMPARATOR", "description": "Inhaled Nitric Oxide (iNO) at 40 parts per million (ppm)", "interventionNames": ["Drug: Nitric Oxide"]}, {"label": "Nitrogen", "type": "PLACEBO_COMPARATOR", "description": "Nitrogen (N2) administered at 40 ppm.", "interventionNames": ["Drug: Nitrogen"]}], "interventions": [{"type": "DRUG", "name": "Nitric Oxide", "description": "40 ppm of Nitric Oxide continuously administered for 48 hours", "armGroupLabels": ["Inhaled Nitric Oxide"], "otherNames": ["INOmax"]}, {"type": "DRUG", "name": "Nitrogen", "description": "Nitrogen (N2) administered at 40 ppm for 48 hours", "armGroupLabels": ["Nitrogen"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Number of Subjects With Left Ventricular Failure During Left Ventricular Assistance Device (LVAD) Placement After Cardio Pulmonary Bypass, as Determined by Failure Criteria, After Administration of Nitric Oxide.", "description": "Failure criteria used to measure outcome includes:\n\n* Left ventricular flow rate index (LVFRI) \u2264 2.0 L/min/m\\^2\n* Administration of \u2265 20 inotropic equivalents (IE)\n* Mean arterial pressure (MAP) \u2264 55 mm Hg\n* Central venous pressure (CVP) \u2265 16 mm Hg\n* Percentage of mixed venous oxygen saturation (SvO2) of \u2264 55% OR failure to wean from cardio pulmonary bypass (CPB) at least once due to hemodynamic failure or death.", "timeFrame": "28 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Scheduled to undergo their first LVAD implantation, (or at least 6 months after explanation of a previous LVAD).\n* Has a pulmonary vascular resistance of at least 2.5 Wood units (200 dynes/sec.) in the 30 days prior to LVAD placement.\n* Greater than 18 years of age.\n* Signed IRB approved informed consent.\n\nExclusion criteria:\n\n* Patients with congestive heart failure due to giant cell myocarditis or restrictive cardiomyopathy.\n* Elective Biventricular Assist Device (BiVAD) surgery, or current support with a temporary BiVad.\n* LVAD procedure expected to be done without cardiopulmonary bypass.\n* Pregnancy (a negative pregnancy test must be documented prior to enrollment).\n* Received nitric oxide by inhalation therapy within the past 24 hours.\n* Investigational drugs that are expected to change systemic or pulmonary vascular resistance are not allowed.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "James Baldassarre, MD", "affiliation": "Mallinckrodt", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Newark Beth Isreal Medical Center", "city": "Newark", "state": "New Jersey", "zip": "07112", "country": "United States", "geoPoint": {"lat": 40.73566, "lon": -74.17237}}, {"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "University of Cincinnati", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Cleveland Clinic Foundation", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Allegheny General Hospital", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15212", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Baylor University Medical Center", "city": "Dallas", "state": "Texas", "zip": "75226", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "University of Texas/St. Paul Medical Center", "city": "Dallas", "state": "Texas", "zip": "75390", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Texas Heart Institute", "city": "Houston", "state": "Texas", "zip": "20345", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Herz-und Diabeteszentrum Nordrhein-Westfalen", "city": "Gergstrab", "state": "Bad Oeynhausen", "zip": "32545", "country": "Germany"}, {"facility": "Deutsches Herfzzentrum Berlin", "city": "Augustenburger Platz", "state": "Berlin", "zip": "13353", "country": "Germany"}, {"facility": "Harefield Hospital", "city": "Harefield", "state": "Middlesex", "zip": "UB96JH", "country": "United Kingdom", "geoPoint": {"lat": 51.60333, "lon": -0.48546}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "There were 8 study medical centers that participated and enrolled subjects; 6 centers in the United States and 2 centers in Germany. There were 150 subjects enrolled in the study.", "groups": [{"id": "FG000", "title": "Inhaled Nitric Oxide", "description": "Inhaled Nitric Oxide (iNO) administered through the INOvent delivery system to subjects at 40 parts per million (ppm) for up to 48 hours"}, {"id": "FG001", "title": "Nitrogen", "description": "Nitrogen (N2) administered through the INOvent delivery system to subjects at 40 ppm for up to 48 hours."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "73"}, {"groupId": "FG001", "numSubjects": "77"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "68"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "9"}]}], "dropWithdraws": [{"type": "Change in surgical plan", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Subinvestigator unavailable", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Inhaled Nitric Oxide", "description": "Inhaled Nitric Oxide (iNO) administered through the INOvent delivery system to subjects at 40 parts per million (ppm) for up to 48 hours"}, {"id": "BG001", "title": "Nitrogen", "description": "Nitrogen (N2) administered through the INOvent delivery system to subjects at 40 ppm for up to 48 hours."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "150"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "150"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.6", "spread": "9.75"}, {"groupId": "BG001", "value": "54.0", "spread": "11.95"}, {"groupId": "BG002", "value": "55.8", "spread": "11.04"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "21"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "65"}, {"groupId": "BG002", "value": "129"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "80"}]}]}, {"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "70"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Number of Subjects With Left Ventricular Failure During Left Ventricular Assistance Device (LVAD) Placement After Cardio Pulmonary Bypass, as Determined by Failure Criteria, After Administration of Nitric Oxide.", "description": "Failure criteria used to measure outcome includes:\n\n* Left ventricular flow rate index (LVFRI) \u2264 2.0 L/min/m\\^2\n* Administration of \u2265 20 inotropic equivalents (IE)\n* Mean arterial pressure (MAP) \u2264 55 mm Hg\n* Central venous pressure (CVP) \u2265 16 mm Hg\n* Percentage of mixed venous oxygen saturation (SvO2) of \u2264 55% OR failure to wean from cardio pulmonary bypass (CPB) at least once due to hemodynamic failure or death.", "populationDescription": "The analysis was determined for intent-to-treat population.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2010-08", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "28 days", "groups": [{"id": "OG000", "title": "Inhaled Nitric Oxide", "description": "Inhaled Nitric Oxide (iNO) administered through the INOvent delivery system to subjects at 40 parts per million (ppm) for up to 48 hours"}, {"id": "OG001", "title": "Nitrogen", "description": "Nitrogen (N2) administered through the INOvent delivery system to subjects at 40 ppm for up to 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "12"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Inhaled Nitric Oxide", "description": "Inhaled Nitric Oxide (iNO) administered through the INOvent delivery system to subjects at 40 parts per million (ppm) for up to 48 hours", "seriousNumAffected": 7, "seriousNumAtRisk": 73, "otherNumAffected": 14, "otherNumAtRisk": 73}, {"id": "EG001", "title": "Nitrogen", "description": "Nitrogen (N2) administered through the INOvent delivery system to subjects at 40 ppm for up to 48 hours.", "seriousNumAffected": 11, "seriousNumAtRisk": 77, "otherNumAffected": 6, "otherNumAtRisk": 77}], "seriousEvents": [{"term": "Right Ventricular Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 77}]}, {"term": "Postprocedural hemorrhage", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 77}]}, {"term": "Hemorrhage", "organSystem": "Vascular disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 77}]}, {"term": "Haemothorax", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}]}, {"term": "Thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}]}, {"term": "Procedural Complication", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}], "otherEvents": [{"term": "Haemorrhagic Anaemia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Coagulopathy", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Right Ventricular Dysfunction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}]}, {"term": "Supraventricular Tachycardia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Ventricular Tachycardia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}]}, {"term": "Hypothermia", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Pyrexia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Central Venous Pressure Decreased", "organSystem": "Investigations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Alanine Aminotransferase Increased", "organSystem": "Investigations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Aspartate Aminotransferase Abnormal", "organSystem": "Investigations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Hypocalcaemia", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Renal Failure Acute", "organSystem": "Renal and urinary disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}, {"term": "Respiratory Disorder", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}]}, {"term": "Cerebrovascular Accident", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}]}, {"term": "Pharyngeal Injury", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}]}, {"term": "Haemodynamic Instability", "organSystem": "Vascular disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 77}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Lawrence Hill", "organization": "Mallinckrodt", "email": "lawrence.hill@mallinckrodt.com", "phone": "908-238-6370"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Congestive Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000009569", "term": "Nitric Oxide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000016166", "term": "Free Radical Scavengers"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045462", "term": "Endothelium-Dependent Relaxing Factors"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000064426", "term": "Gasotransmitters"}, {"id": "D000020011", "term": "Protective Agents"}], "browseLeaves": [{"id": "M12507", "name": "Nitric Oxide", "asFound": "Side effects", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M25496", "name": "Endothelium-Dependent Relaxing Factors", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}